Caractérisation moléculaire de l'EGFR dans les cancers bronchiques non à petites cellules : étude prospective comparative des technologies NGS et automate Idylla, Annales de pathologie, 2020. ,
, Références [1] Rapport interactifLes cancers en France -édition, 2017.
,
ErbB receptors and signaling pathways in cancer, Curr Opin Cell Biol, vol.21, pp.177-84, 2009. ,
New driver mutations in non-small-cell lung cancer, Lancet Oncol, vol.12, pp.175-80, 2011. ,
Beyond histology: translating tumor genotypes into clinically effective targeted therapies, Clin Cancer Res, vol.20, pp.2264-75, 2014. ,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, vol.361, pp.947-57, 2009. ,
Superior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection of SNPs and Clustered Mutations in qPCR, PLOS ONE, vol.12, p.170087, 2017. ,
Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer, Oncotarget, vol.8, pp.103055-62, 2017. ,
Influence de la cellularité tumorale dans la recherche des mutations des cancers du poumon : expérience du centre Paul Papin (Angers), 2015. ,
, ©Mutations de l'EGFR dans le cancer du poumon : mise en évidence d'une cible moléculaire permettant un accès spécifique aux thérapies ciblées, 2010.
Managing acquired resistance in EGFRmutated non-small cell lung cancer, Clin Adv Hematol Oncol HO, vol.13, pp.528-560, 2015. ,
Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance, Cancer Med, vol.4, pp.1621-1653, 2015. ,
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway, Clin Lung Cancer, vol.10, pp.281-290, 2009. ,
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations -a review, Transl Lung Cancer Res, vol.4, pp.67-81, 2015. ,
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor--resistant non-small cell lung cancer, Transl Lung Cancer Res, vol.3, pp.370-372, 2014. ,
Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015. ,
Implementing multiplexed genotyping of non-smallcell lung cancers into routine clinical practice, Ann Oncol, vol.22, pp.2616-2640, 2011. ,
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov, Internet], 2018. ,
, Genetically Informed Cancer Medicine -My Cancer Genome
,